Assessing the Safety and Tolerability of NMN in DHDDS-CDG

Summary

The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol diphosphate synthase congenital disorder of glycosylation (DHDDS-CDG). This will to contribute to knowledge that will allow healthcare providers to make informed decisions about recommending this dietary supplement in this population.

Timeline

Start

2026-05-08

Primary completion

2027-08-01

Completion

2027-08-01

Drugs

Indications